Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Senda Biosciences is raising $123,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Guillaume Pfefer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Senda Biosciences
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells both within the cell (mRNA), and, remarkably, to the cell – using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Sendas proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.

To learn more about Senda Biosciences, visit http://www.sendabiosciences.com/

Contact:
Guillaume Pfefer, Chief Executive Officer
617-430-4455
gpfefer@sendabiosciences.com
https://www.linkedin.com/in/guillaumepfefer/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved